Press release
August 3, 2016
J. Aaron Grantham, MD, Joins Corindus Vascular Robotics as Chief Medical Officer

Dr. Grantham will lead initiatives to educate the interventional cardiology community on benefits of robotic therapy

WALTHAM, MA - August 3, 2016Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that J. Aaron Grantham, MD, a leading interventional cardiologist, and an innovator in the treatment of chronic total occlusions (CTOs), has joined the company as Chief Medical Officer (CMO).

Dr. Grantham AaronDr. Grantham will be spearheading Corindus' initiatives to educate the interventional cardiology community on the benefits of robotic therapy and will be leading efforts to develop clinical data to advance the CorPath® System’s applicability for additional clinical indications. As a practicing CMO, Dr. Grantham will continue treating patients at Saint Luke's Mid America Heart Institute.

"I am excited to be joining Corindus during this time of growth for the company," said Dr. Grantham. "I believe that through a systematic, program-based approach, similar to my work in building CTO programs, robotic therapy will be able to reach its full potential. I look forward to working with other leaders in the field of interventional cardiology as we continue to optimize robotic therapy."

Dr. Grantham is with Saint Luke’s Mid America Heart Institute, a member of Saint Luke’s Health System, as Associate Professor, University of Missouri-Kansas City School of Medicine. He also is Director of the school’s Cardiovascular Disease Fellowship Program and Director of Cardiovascular Medical Education at Saint Luke’s Hospital.

"Dr. Grantham’s experience, knowledge and thought leadership will play an integral role in our continued growth and success,” said Mark Toland, President and Chief Executive Officer of Corindus “Together with an esteemed steering committee, Dr. Grantham will help Corindus achieve our vision and build a strong clinical roadmap for CorPath. We are excited to welcome him to the company in this critical position."

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
close the window

Please complete the form below in order to download the content.

close the window

Please complete the form below in order to download the content.

close the window

Please fill out this brief form to subscribe to our email newsletter. By submitting this form, I consent to receive email communications from Corindus.

close the window

Please complete the form below and a member of our Clinical team will contact you.

close the window

Please complete the form below in order to download the content.

close the window

The page you wish to view contains content that is not available in all regions. Please select your region.

close the window